Unlabelled: Hidradenitis suppurativa (HS) is a chronic suppurative disease impairing patients' quality of life (QOL). The standard treatment remains extensive surgery; medical treatment is often disappointing.
Objectives: Prolonged infliximab efficacy and tolerance in moderate-to-severe forms of HS were evaluated.
Patients And Methods: This prospective, monocentric, open, interventional study concerned patients with progressive, moderate-to-severe HS ineligible for surgery, or who relapsed after surgery. Infliximab (5 mg/kg) was infused at weeks 0, 2 and 6, and then every 4 weeks. When the response was satisfactory, infusion spacing was attempted.
Results: Ten patients were included, 8 treated for 1 year, with a mean of 5 affected sites and 18 years of evolution. The mean initial DLQI was 20/30 (range 9-30). At 1 year, the number of involved sites (P<0.001) and flares (P<0.05) had decreased significantly under infliximab, as did HS severity. QOL improved clearly and rapidly for all patients, with mean DLQI at 6/30 (P<0.001). Tolerance was satisfactory with only 4 minor infections, 1 keratoacanthoma and one rapidly resolving hepatitis.
Conclusion: This evaluation of prolonged infliximab use in HS after surgical failure showed good efficacy and satisfactory tolerance without therapeutic escape during the first year of treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/ejd.2012.1795 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
CNS Drugs
January 2025
School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.
Background: Epstein-Barr virus (EBV) is implicated as a necessary factor in the development of multiple sclerosis (MS) and may also be a driver of disease activity. Although it is not clear whether ongoing viral replication is the driver for MS pathology, MS researchers have considered the prospect of using drugs with potential efficacy against EBV in the treatment of MS. We have undertaken scientific and lived experience expert panel reviews to shortlist existing licensed therapies that could be used in later-stage clinical trials in MS.
View Article and Find Full Text PDFGanaxolone: A Review in Epileptic Seizures Associated with Cyclin-Dependent Kinase-Like 5 Deficiency Disorder.
Paediatr Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral ganaxolone (ZTALMY), a synthetic analogue of the endogenous neuroactive steroid allopregnanolone, acts as a positive allosteric modulator of synaptic and extra-synaptic γ-aminobutyric acid (GABA) type A receptor function in the CNS. In the EU and the UK, it is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2-17 years. In a multinational phase III study (Marigold), 17 weeks' therapy with adjunctive ganaxolone, administered orally three times daily with food, significantly reduced 28-day major motor seizure frequency from baseline versus placebo in patients aged 2-19 years with CDD-associated refractory epilepsy.
View Article and Find Full Text PDFTranscranial direct current stimulation (tDCS) in psychiatric disorders in early childhood (aged under 10 years): a systematic review.
Eur Child Adolesc Psychiatry
January 2025
Department of Psychiatry, Neurology, Psychotherapy and Psychosomatics in Childhood and Adolescence, Rostock University Medical Center, Gehlsheimer Straße 20, 18147, Rostock, Germany.
Transcranial direct current stimulation (tDCS) remains experimental for many psychiatric disorders in adults. Particularly in childhood, there is limited research on the evidence for the efficacy and mechanisms of action of tDCS on the developing brain. The objective of this review is to identify published experimental studies to examine the efficacy and mechanisms of tDCS in children with psychiatric or developmental disorders in early (prepubertal) childhood (aged under 10 years).
View Article and Find Full Text PDFStrategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective.
Clin Transl Oncol
January 2025
Medical Oncology Department, Hospital del Mar, Parc de Salut Mar, Spanish Group for Breast Cancer Research (GEICAM), Barcelona, Spain.
Therapeutic decision-making for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer highlights the importance of a comprehensive geriatric assessment (CGA). This assessment considers the functional status, comorbidities, and relevant conditions of the patient, and allows for an estimation of life expectancy, but it does not facilitate individualized treatment plans. There are also other challenges to consider related to the cardiac toxicity of the treatments and the under-representation of older patients in clinical trials.
View Article and Find Full Text PDFSeltorexant for major depressive disorder.
Expert Opin Emerg Drugs
January 2025
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Introduction: Preclinical and clinical pharmacologic evidence indicate that orexin systems are relevant to sleep-wake cycle regulation and dimensions of reward and cognition, providing the basis to hypothesizing that they may be effective as therapeutics in mental disorders. Due to the limited efficacy and tolerability profiles of existing treatments for Major Depressive Disorder (MDD), investigational compounds in novel treatment classes are needed; seltorexant, an orexin receptor antagonist, is a potential new treatment currently under investigation.
Areas Covered: Mechanisms implicated in MDD, including reward and sleep are first overviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!